NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 3 3
ROE
(50.60%) (38.89%) (49.96%) (43.22%)
ROA
(13.75%) (13.32%) (16.99%) (14.56%)
ROIC
0.00% (123.24%) (92.52%) (115.56%)
Return on Tangible Assets
(33.88%) (26.04%) (33.69%) (28.58%)
Average Days of Receivables
70.88 82.49 79.24 76.12
Free Cash Flow per Share
(0.58) (0.68) (0.42) (0.22)
Free Cash Flow
(65.17) (75.68) (48.07) (25.43)
Capital Expenditures
(30.69) (26.65) (21.19) (22.62)
Other line items
Cash ROIC
(4.15%) (7.62%) (4.77%) (2.58%)
Accounts Receivable Turnover
5.91 5.09 5.09 5.09
Accounts Payable Turnover
1.50 1.47 1.50 1.42
Inventory Turnover
4.05 4.38 4.03 4.05
Average Days of Payables
274.40 267.35 277.62 285.86
Days of Inventory on Hand
90.23 89.92 94.82 92.33
Tax Rate
0.18 0.00 (0.01) (0.03)
Research and Development Expense of Revenue
33.45% 34.26% 33.97% 32.14%
Selling, General and Administrative Expense of Revenue
69.43% 63.74% 68.41% 66.07%
Share Based Compensation of Revenue
23.01% 16.00% 20.51% 18.47%
Interest Coverage
6.74 8.76 22.52 90.29
Operating CF/Net income
0.19 0.36 0.16 0.02
Depreciation/Fixed assets
(0.13) (0.09) (0.04) 0.01
Capex/Depreciation
2.43 3.09 5.61 (23.71)
Revenue per Share
5.74 5.88 5.91 6.03
Operating CF per Share
(0.31) (0.44) (0.24) (0.02)
Capex per Share
(0.27) (0.24) (0.19) (0.19)
Capex to Sales
0.05 0.04 0.03 0.03

Fold the line items

Columns are period end dates